Q4 Preview: How Will Bayer Survive Patent Cliff?
Executive Summary
Ahead of the German major's fourth-quarter earnings call Feb. 27, analysts at Bernstein have been weighing up Bayer's chances of surviving the patent expiries on Xarelto and Eylea.
You may also be interested in...
Building Bayer For The Next Decade And Navigating A Patent Cliff
As Bayer prepares for several of its key products to lose patent exclusivity in four to five years’ time, In Vivo caught up with the company’s new head of pharma, Stefan Oelrich, to hear more on his strategy for the future – especially his plans for drug R&D, collaboration and a pipeline built on external innovation.
Bayer Confident It Can Cope With Patent Cliff Pain
The German major noted that the effects of the losses of patent protection on Xarelto and Eylea are still about five years down the line and it expects to be able to soften the blow with some future big-earners from the pipeline and more external deals.
Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.